John Cox, DO
Cardiovascular Disease · Joplin, MONPI 1669418612
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $3,165 of the $4,841 with a category attached, or 65.4%. 8 manufacturers reported payments, led by Medtronic at 45.7% of the total. Reporting peaked in 2022 at $2,400 and has fallen 93.7% since, to $151 in 2025.
Across 32 payments — averaging $151.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Penumbra, Inc.$2K
- Abiomed$268
- Shockwave Medical, Inc$175
- Heartflow, Inc.$19
- Boston Scientific$18
- plus $28 from 2 others
Across 1 payment — averaging $1609.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$2K
What the payments were for
- Travel & lodging$3,16565%
- Food & beverage$1,67635%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 17 | $2,212 |
| Penumbra, Inc. | 6 | $2,120 |
| Abiomed | 3 | $268 |
| Shockwave Medical, Inc | 2 | $175 |
| Heartflow, Inc. | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo$2,120
- Impella$120
- AZURE XT DR MRI SURESCAN$109
How this compares
$4,841 in reported general payments places this provider in the 70th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 906 | $681,128 |
| EntrestoSacubitril/Valsartan | 252 | $205,595 |
| XareltoRivaroxaban | 195 | $133,151 |
| Repatha SureclickEvolocumab | 41 | $26,245 |
| FarxigaDapagliflozin Propanediol | 29 | $21,184 |
| Flecainide Acetate | 481 | $19,947 |
| JardianceEmpagliflozin | 18 | $9,259 |
| BrilintaTicagrelor | 12 | $5,326 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 22 | $4,532 |
| Metoprolol Succinate | 495 | $4,005 |
| Atorvastatin Calcium | 547 | $3,524 |
| Carvedilol | 732 | $3,503 |
| Spironolactone | 693 | $3,486 |
| Amiodarone Hcl | 255 | $3,070 |
| ClopidogrelClopidogrel Bisulfate | 422 | $2,935 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Joplin
- Christopher LongneckerJoplin$29K
- William NicholasJoplin$22K
- Mikhail KosiborodKansas City$1.1M
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- John SpertusKansas City$360K
- James FairlambColumbia$342K
- James EllisonChesterfield$267K
- Osler Jay GuzonSaint Louis$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.